Wu X, et al. - Researchers sought to assess effective biomarkers that can improve overall diagnosis and treatment of hepatocellular carcinoma (HCC) via a meta-analysis of all relevant studies reporting the clinicopathological significance of CDH1 hypermethylation in HCC by using Review Manager 5.2. HCC tissue displayed a significantly higher positive rate of CDH1 hypermethylation vs normal liver tissue. Compared to the group of chronic liver disease, CDH1 promoter in HCC was more frequently hypermethylated. They observed better overall survival has significant correlation with high CDH1 mRNA expression in all 231 HCC patients vs 133 HCC patients with low-level CDH1 mRNA expression. These findings suggest that for HCC carcinogenesis and diagnosis, CDH1 promoter hypermethylation is a risk factor and promising biomarker.